Human-based in vitro experimental systems for the evaluation of human drug safety

Current Drug Safety

Volumn 2, Issue 3, 2007, Pages 193-199

  Li, Albert P ^a  

^a Advanced Pharmaceutical Sciences Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9 AMINOCAMPTOTHECIN; ALCOHOL; AMINEPTINE; CADMIUM CHLORIDE; CAMPTOTHECIN; CHLORZOXAZONE; CISPLATIN; COCAINE; COUMARIN; CYCLOPHOSPHAMIDE; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 3A7; ERYTHROMYCIN; HALOTHANE; IMIPRAMINE; ISAXONINE; MEPHENYTOIN; METHYLDOPA; NEW DRUG; PARACETAMOL; PHENYTOIN; TESTOSTERONE; TIENILIC ACID; TOLBUTAMIDE; TOPOTECAN; UNINDEXED DRUG;

ACCURACY; CARDIOTOXICITY; CELL CULTURE; CELL POPULATION; CHOLESTASIS; COCULTURE; CYTOTOXICITY; DRUG EFFICACY; DRUG HYDROXYLATION; DRUG INDUSTRY; DRUG MARKETING; DRUG METABOLISM; DRUG RESEARCH; DRUG SAFETY; EXPERIMENTAL MODEL; EXPERIMENTATION; FINANCIAL MANAGEMENT; FOOD AND DRUG ADMINISTRATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIPIDOSIS; LIVER MICROSOME; LIVER TOXICITY; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; OUTCOME ASSESSMENT; PATIENT SELECTION; PHARMACOPHORE; PREDICTION; PRIORITY JOURNAL; RESEARCH ETHICS; RESEARCH SUBJECT; REVIEW; SPECIES DIFFERENCE; STEATOSIS; TARGET CELL; THEORY; TOXICITY TESTING; TOXICOGENETICS; TOXICOKINETICS; TREATMENT OUTCOME; UNITED STATES;

ANIMALS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUG TOXICITY; FORECASTING; HUMANS; ORGAN CULTURE TECHNIQUES; PHARMACEUTICAL PREPARATIONS; SPECIES SPECIFICITY;

EID: 35348893768     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488607781668909     Document Type: Review

References (33)

1. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003; 22(2): 151-85.
2. Easterbrook J, Fackett D, Li AP. A comparison of aroclor 1254-induced and uninduced rat liver microsomes to human liver microsomes in phenytoin O-deethylation, coumarin 7-hydroxylation, tolbutamide 4-hydroxylation, S-mephenytoin 4′-hydroxylation, chloroxazone 6-hydroxylation and testosterone 6beta-hydroxylation. Chem Biol Interact 2001; 134(3): 243-9.
3. Erickson-Miller CL, May RD, Tomaszewski J, et al. Differential toxicity of camptothecin, topotecan and 9-aminocamptothecin to human, canine, and murine myeloid progenitors (CFU-GM) in vitro. Cancer Chemother Pharmacol 1997; 39(5): 467-72.
4. Huang SM, Lesko LJ, William RL. Assessment of the quality and quantity of drug-drug interaction studies in recent NDA submissions: study design and data analysis issues. J Clin Pharmacol 1999; 39(10): 1006-14.
5. Davit B, Reynolds K, Yuan R, et al. FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug-drug interactions: impacit on labeling. J Clin Pharmacol 1999; 39(9): 899-910.
6. Li, AP. In vitro approaches to evaluate ADMET drug properties. Curr Top Med Chem 2004a; 4(7): 701-6.
7. FDA (1997). Drug Metabolism/Drug Interaction Studies in the Drug Development Process: 'Studies In Vitro (Issued 4/1997, Posted 4/8/ 1997). http://www.fda.gov/cder/guidance/clin3.pdf.
8. (a) FDA (1999). In Vivo Drug Metabolism/Drug Interaction Studies - Study Design, Data Analysis, and Recommendations for Dosing and Labeling (Issued 11/24/1999, Posted 11/24/1999). http://www.fda.gov/cder/guidance/ 2635fnl.pdf.
9. (b) Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004; 3: 711-715.
10. MacGregor JT, Collins JM, Sugiyama Y, et al. In vitro human tissue models in risk assessment: report of a consensus-building workshop. Toxicol Sci 2001; 59(1): 17-36.
11. Li AP, Lu C, Brent JA, et al. Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential. Chem Biol Interact 1999; 121(1): 17-35.
12. Shitara Y, Itoh T, Sato H, Li AP, Sugiyama Y. Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther 2003; 304(2): 610-6.
13. Jigorel E, Le Vee M, Boursier-Neyret C, Bertrand M, Fardel O. Functional expression of sinusoidal drug transporters in primary human and rat hepatocytes. Drug Metab Dispos 2005; 33(10): 1418-22.
14. Rodriguez-Antona C, Donato MT, Boobis A, et al. Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: molecular mechanisms that determine lower expression in cultured cells. Xenobiotica 2002; 32(6): 505-20.
15. Li AP. An integrated, multidisciplinary approach for drug safety assessment. Drug Discov Today 2004b; 9(16): 687-93.
16. Li AP. A comprehensive approach for drug safety assessment. Chem Biol Interact 2004c; 150(1): 27-33.
17. (a) Li AP. Human hepatocytes: Isolation, cryopreservation and applications in drug development. Chem Biol Interact 2007; 168(1): 16-29.
18. (b) Ganey PE, Luyendyk JP, Maddox JF, Roth RA. Adverse hepatic drug reactions: inflammatory episodes as consequence and contributor. Chem Biol Interact 2004; 150(1): 35-51.
19. Hewitt NJ, Lloyd S, Hayden M, et al. Correlation between troglitazone cytotoxicity and drug metabolic enzyme activities in cryopreserved human hepatocytes. Chem Biol Interact 2002; 142(1-2): 73-82.
20. Lloyd S, Hayden MJ, Sakai Y, et al. Differential in vitro hepatotoxicity of toglitazone and rosiglitazone among cryopreserved human hepatocytes from 37 donors. Chem Biol Interact 202; 142(1-2): 57-71.
21. Hartman NR, Cysyk RL, Bruneau-Wack C, Thenot JP, Parker RJ, Strong JM. Production of intracellular 35S-glutathione by rat and human hepatocytes for the quantification of xenobiotic reactive intermediates. Chem Biol Interact 2002; 142(1-2): 43-55.
22. Prabhu S, Fackett A, Lloyd S, et al. Identification of glutathione conjugates of troglitazone in human hepatocytes. Chem Biol Interact 2002; 142(1-2): 83-97.
23. Zhang Z, Chen Q, Li Y, et al. In vitro bioactivation of dihydrobenoxathiin selective estrogen receptor modulators by cytochrome P450 3A4 in human liver microsomes: formation of reactive iminium and quinone type metabolites. Chem Res Toxicol 2005; 18(4): 675-85.
24. Cysyk RL, Parker RJ, Barchi JJ Jr, Steeg PS, Hartman NR, Strong JM. Reaction of geldanamycin and C17-substituted analogues with glutathione: product identifications and pharmacological implications. Chem Res Toxicol 2006; 19(3): 376-81.
25. Amacher DE, Martin BA. Tetracycline-induced steatosis in primary canine hepatocyte cultures. Fundam Appl Toxicol 1997; 40(2): 256-63.
26. Sahi J, Sinz MW, Campbell S, et al. Metabolism and transporter-mediated drug-drug interactions of the endothelin-A receptor antagonist CI-1034. Chem Biol Interact 2006; 159(2): 156-68.
27. Kasahara T, Tomita K, Murano H, et al. Establishment of an in vitro high-thoughtput screening assay for detecting phospholipidosis-inducing potential. Toxicol Sci 2006; 90(1): 133-41.
28. Reasor MJ, Hastings KL, Ulrich RG. Drug-induced philspholipidosis: issues and future directions. Expert Opin Drug Saf 2006, 5(4): 567-83.
29. Li AP. A review of the common properties of drugs with idiosyncratic hepatotoxicity and the "multiple determinant hypothesis" for the manifestation of idiosyncratic drug toxicity. Chem Biol Interact 2002; 142(1-2): 7-23.
30. Kier LD, Neft R, Tang L, et al. Applications of microarrays with toxicologically relevant genes (tox genes) for the evaluation of chemical toxicants in Sprague Dawley rats in vivo and human hepatocytes in vitro. Mutat Res 2004; 549(1-2): 101-13.
31. Liguori MJ, Anderson MG, Bukofzer S, et al. Microarray analysis in human hepatocytes suggests a mechanism for hepatotoxicity induced by trovafloxacin. Hepatology 2005; 41(1): 177-86.
32. Li AP, Bode C, Sakai Y. A novel in vitro system, the integrated discrete multiple organ cell culture (IdMOC) system, for the evaluation of human drug toxicity: comparative cytotoxicity of tamoxifen towards normal human cells frorm five major organs and MCF4 adenocarcinoma breast cancer cells. Chem Biol Interact 2004; 150(1): 129-36.
33. Baillie TA. Future of toxicology-metabolic activation and drug design: challenges and opportunities in chemical toxicology. Chem Res Toxico 2006; 19(7): 889-93.